Safety and Preliminary Anti-Tumor Activity of TYRA-430
Phase 1
100
about 3.4 years
18+
9 sites in CA, KS, MA +4
What this study is about
Researchers are testing the safety, tolerability, and how well TYRA-430 works against cancer cells with FGF/FGFR pathway problems. The trial will last for about 1255 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take TYRA-430
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Maximum tolerated dose (MTD), Rate and severity of adverse events of TYRA-430 as monotherapy
Secondary: Cmax, Disease Control Rate (DCR), Duration of Response (DOR), Overall Response Rate (ORR), Time to Response (TTR), Tmax, t1/2
Oncology